PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Finan, B. ; Müller, T.D. ; Clemmensen, C. ; Perez-Tilve, D.* ; Tschöp, M.H.

Reappraisal of GIP pharmacology for metabolic diseases.

Trends Mol. Med. 22, 359-376 (2016)
DOI PMC
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Glucagon-like peptide-1 (GLP-1) analogs are considered the best current medicines for type 2 diabetes (T2D) and obesity due to their actions in lowering blood glucose and body weight. Despite similarities to GLP-1, glucose-dependent insulinotropic polypeptide (GIP) has not been extensively pursued as a medical treatment for T2D. This is largely based on observations of diminished responses of GIP to lower blood glucose in select patients, as well as evidence from rodent knockout models implying that GIP promotes obesity. These findings have prompted the belief in some, that inhibiting GIP action might be beneficial for metabolic diseases. However, a growing body of new evidence - including data based on refined genetically modified models and improved pharmacological agents - suggests a paradigm shift on how the GIP system should be manipulated for metabolic benefits.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
9.292
2.399
67
91
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Schlagwörter Dependent Insulinotropic Polypeptide; Gastric-inhibitory Polypeptide; Glucagon-like Peptide-1; High-fat Diet; Pancreatic Beta-cells; Improves Glucose-tolerance; Type-2 Diabetes-mellitus; Receptor Knockout Mice; Rat Adipose-tissue; Blood-glucose
Sprache
Veröffentlichungsjahr 2016
HGF-Berichtsjahr 2016
ISSN (print) / ISBN 1471-4914
e-ISSN 1471-499X
Zeitschrift Trends in Molecular Medicine
Quellenangaben Band: 22, Heft: 5, Seiten: 359-376 Artikelnummer: , Supplement: ,
Verlag Elsevier
Verlagsort Oxford
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Diabetes and Obesity (IDO)
POF Topic(s) 30201 - Metabolic Health
90000 - German Center for Diabetes Research
Forschungsfeld(er) Helmholtz Diabetes Center
PSP-Element(e) G-502200-001
G-501900-221
DOI 10.1016/j.molmed.2016.03.005
WOS ID WOS:000375814100004
Scopus ID 84962046497
PubMed ID 27038883
Erfassungsdatum 2016-04-15
[➜Korrektur melden]